Cenegermin is a recombinant human nerve growth factor used to treat neurotrophic keratitis. Cenegermin is a human beta-nerve growth factor (beta-ngf)-(1-118)- peptide (non-covalent dimer) produced in escherichia coli.
- Mechanism
- Curator reviewed · 3 references
Cenegermin is a recombinant form of human nerve growth factor.
Neurotrophic keratitis is a degenerative disease resulting from a loss of corneal sensation. The loss of corneal sensation impairs corneal health, causing progressive damage to the top layer of the cornea, including corneal thinning, ulceration, and perforation in severe cases.
Nerve growth factor is subsequently an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e., TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors. Nerve growth factor receptors are expressed in the anterior segment of the eye (cornea, conjunctiva, iris, ciliary body, and lens), by the lacrimal gland, and by posterior segment intraocular tissues. The treatment with cenegermin, administered as eye drops, is intended to allow restoration of corneal integrity.
- Primary indication
- Cenegermin is indicated for the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults by the FDA and EMA.Curator reviewed · 3 structured indications
- Formula / weight
- C583H908N166O173S8 · 13226.0 Da
- First approval
- Canada, 2019 · United States, 2018 · European Union, 2020
- Also known as
- cenegermin-bkbj
- Brand names
Resolves to
What you can answer from here — as of May 06, 2025
Which drugs share a target with Cenegermin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account